BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Famitinib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Famitinib\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07143292-2035@assetmemo.bio
DTSTAMP:20261121T005716Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Famitinib: Phase 2 readout est. (NCT07143292)
DESCRIPTION:Famitinib\, phase 2\, Cervical Cancer.\nStudy: A Prospective\, 
 Randomized\, Parallel Trial of Famitinib Malate at Different Doses Combine
 d With Camrelizumab for the Treatment of Recurrent and Metastatic Cervical
  Cancer\nEstimated primary completion: 30 December 2026. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/famitinib#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07143292
URL:https://assetmemo.bio/drug/famitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06306560-2035@assetmemo.bio
DTSTAMP:20261121T005716Z
DTSTART;VALUE=DATE:20270315
DTEND;VALUE=DATE:20270316
SUMMARY:Famitinib: Phase 2 readout est. (NCT06306560)
DESCRIPTION:Famitinib\, phase 2.\nStudy: A Study of Adebrelimab Combined Wi
 th Famitinib and Chemotherapy in the Treatment of ES-SCLC.\nEstimated prim
 ary completion: 15 March 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/famitinib#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06306560
URL:https://assetmemo.bio/drug/famitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06332950-2035@assetmemo.bio
DTSTAMP:20261121T005716Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Famitinib: Phase 1/2 readout est. (NCT06332950)
DESCRIPTION:Famitinib\, phase 1/2.\nStudy: Safety and Efficacy of Adebrelim
 ab Plus Irinotecan Liposome (II) With or Without Famitinib in ES-SCLC Pre-
 treated With Immunotherapy\nEstimated primary completion: 1 April 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/famitinib#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06332950
URL:https://assetmemo.bio/drug/famitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07309185-2035@assetmemo.bio
DTSTAMP:20261121T005716Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Famitinib: Phase 2 readout est. (NCT07309185)
DESCRIPTION:Famitinib\, phase 2.\nStudy: Adebrelimab Combined With Famitini
 b and Irinotecan in Advanced Gastric Cancer After Failure of First-Line Th
 erapy\nEstimated primary completion: 31 July 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/famitinib#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07309185
URL:https://assetmemo.bio/drug/famitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07814859-2035@assetmemo.bio
DTSTAMP:20261121T005716Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Famitinib: Phase 2 readout est. (NCT07814859)
DESCRIPTION:Famitinib\, phase 2.\nStudy: Retlirafusp Alfa Combined With Fam
 itinib\, Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patien
 ts With Unresectable Pancreatic Cancer\nEstimated primary completion: 31 A
 ugust 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/famitinib
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT078
 14859
URL:https://assetmemo.bio/drug/famitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07147088-2035@assetmemo.bio
DTSTAMP:20261121T005716Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Famitinib: Phase 2 readout est. (NCT07147088)
DESCRIPTION:Famitinib\, phase 2.\nStudy: Cryoablation Combined With SHR-170
 1 Plus Famitinib in Patients With Advanced Intrahepatic Cholangiocarcinoma
 .\nEstimated primary completion: 1 September 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/famitinib#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07147088
URL:https://assetmemo.bio/drug/famitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07627620-2035@assetmemo.bio
DTSTAMP:20261121T005716Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Famitinib: Phase 2 readout est. (NCT07627620)
DESCRIPTION:Famitinib\, phase 2\, Cervical Cancer.\nStudy: Camrelizumab Com
 bined With Famitinib Malate and Chemotherapy for Treatment of Recurrent/ M
 etastatic Cervical Cancer\nEstimated primary completion: 30 September 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/famitinib#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07627620
URL:https://assetmemo.bio/drug/famitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05749588-2035@assetmemo.bio
DTSTAMP:20261121T005716Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Famitinib: Phase 2 readout est. (NCT05749588)
DESCRIPTION:Famitinib\, phase 2.\nStudy: FUSCC Refractory TNBC Platform Stu
 dy (FUTURE2.0)\nEstimated primary completion: 31 December 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/famitinib#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT05749588
URL:https://assetmemo.bio/drug/famitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05582499-2035@assetmemo.bio
DTSTAMP:20261121T005716Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Famitinib: Phase 2 readout est. (NCT05582499)
DESCRIPTION:Famitinib\, phase 2.\nStudy: Fudan University Shanghai Cancer C
 enter Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy\n
 Estimated primary completion: 31 December 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/famitinib#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT05582499
URL:https://assetmemo.bio/drug/famitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07847710-2035@assetmemo.bio
DTSTAMP:20261121T005716Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Famitinib: Phase 2 readout est. (NCT07847710)
DESCRIPTION:Famitinib\, phase 2.\nStudy: Perioperative Retlirafusp Alfa(Ant
 i-PD-L1/TGF-β Bifunctional Fusion Protein) Plus Famitinib and GEMOX-Based
  Hepatic Arterial Infusion Chemotherapy for Locally Advanced Intrahepatic 
 Cholangiocarcinoma: A Multicenter\, Single-Arm\, Exploratory Phase II Tria
 l\nEstimated primary completion: 1 March 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/famitinib#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07847710
URL:https://assetmemo.bio/drug/famitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07662681-2035@assetmemo.bio
DTSTAMP:20261121T005716Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Famitinib: Phase 1/2 readout est. (NCT07662681)
DESCRIPTION:Famitinib\, phase 1/2.\nStudy: Camrelizumab With Famitinib for 
 Patients With Rare Head and Neck Malignancies\nEstimated primary completio
 n: 1 July 2028. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/famit
 inib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07662681
URL:https://assetmemo.bio/drug/famitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07796113-2035@assetmemo.bio
DTSTAMP:20261121T005716Z
DTSTART;VALUE=DATE:20281030
DTEND;VALUE=DATE:20281031
SUMMARY:Famitinib: Phase 2 readout est. (NCT07796113)
DESCRIPTION:Famitinib\, phase 2.\nStudy: Adebrelimab With Famitinib and Che
 motherapy as Neoadjuvant Therapy for ESCC\nEstimated primary completion: 3
 0 October 2028. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/famit
 inib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07796113
URL:https://assetmemo.bio/drug/famitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07517653-2035@assetmemo.bio
DTSTAMP:20261121T005716Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Famitinib: Phase 2 readout est. (NCT07517653)
DESCRIPTION:Famitinib\, phase 2.\nStudy: Neoadjuvant SHR-1701 Plus Famitini
 b With Response-guided Adjuvant Therapy in Resectable Mucosal Melanoma\nEs
 timated primary completion: 30 November 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/famitinib#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07517653
URL:https://assetmemo.bio/drug/famitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07355010-2035@assetmemo.bio
DTSTAMP:20261121T005716Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Famitinib: Phase 2 readout est. (NCT07355010)
DESCRIPTION:Famitinib\, phase 2.\nStudy: A Randomized\, Open-label\, Double
 -cohort Study of Fluzoparib Combined With Famitinib Malate or SHR-1701 for
  Neoadjuvant Therapy in Patients With Advanced Ovarian Cancer\nEstimated p
 rimary completion: 30 December 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/famitinib#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07355010
URL:https://assetmemo.bio/drug/famitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07382687-2035@assetmemo.bio
DTSTAMP:20261121T005716Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Famitinib: Phase 3 readout est. (NCT07382687)
DESCRIPTION:Famitinib\, phase 3.\nStudy: Famitinib Combined With SHR-A1811\
 , Versus SHR-A1811 for CDK4/6 Inhibitors-resistent Advanced HR+/HER2- Brea
 st Cancer With SNF4 Subtype\nEstimated primary completion: 31 December 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/famitinib#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07382687
URL:https://assetmemo.bio/drug/famitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07382713-2035@assetmemo.bio
DTSTAMP:20261121T005716Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Famitinib: Phase 2 readout est. (NCT07382713)
DESCRIPTION:Famitinib\, phase 2.\nStudy: Fluzoparib Plus Famitinib Maintena
 nce After First-Line Platinum Response in Advanced Ovarian Cancer\nEstimat
 ed primary completion: 31 December 2030. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/famitinib#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07382713
URL:https://assetmemo.bio/drug/famitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
